The period since the public launch of ChatGPT 3.5 in November 2022 has been marked by an unprecedented wave of excitement and investment in Artificial Intelligence (AI) within the life sciences sector. As of July 2025, the
Large‑language models (LLMs) are now being evaluated at every rung of the drug‑development ladder—from candidate‑selection brainstorming to post‑marketing signal detection. The focus of this article is on productivity accelerators rather than high‑stakes, fully autonomous decision making. These are
Nimble Clinical Research, a US-based innovator specializing in AI-powered technology for automating complex clinical trial processes, and CuMinds Innovations, an India-based Knowledge-as-a-Solution (KaaS) provider focused on clinical data science services, today announced a strategic partnership. This collaboration
We are thrilled to announce the launch of our cutting-edge AI-powered platform, specifically designed to revolutionize the way Data Managers approach critical study startup tasks. Say goodbye to tedious manual processes and hello to a new era
Today, I’d like to talk about a common misconception I’ve seen across the industry—in discussions, presentations, and strategy meetings: the belief that before you can use AI, you must first train it. It’s an assumption rooted in
The future of clinical research programming is evolving at breakneck speed. Traditional languages like SAS are no longer our only safe bet. Python and R are no longer niche tools—they’re powerful, and AI-ready. A New Era of
Imagine you're Neo from The Matrix, and you suddenly need to learn kung fu. Instead of enrolling in a dojo, you just download the skill directly into your brain and—boom!—you're a master. That’s essentially what Retrieval-Augmented Generation
As we are embracing AI, it is interesting to look back at the ascension of AI in enhancing data analysis capabilities to support clinical trials. Starting from rule-based systems that required us to manually program every guideline,
Today, I want to delve into the emerging world of AI agents. This brings to mind the iconic scenes from the Matrix movies where Agent Smith replicates, forming an army of agents. While we're not yet facing
The 80-20 rule is often used to describe the imbalance of effort in clinical trials—20% of the standardized work is efficient and straightforward, while the remaining 80% demands deeper expertise, collaboration, and customization. But with the rapid
